Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
PSTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $2.67
Previous CloseN/A
Volume69.06K
Average Volume (3M)32.60M
Market Cap
$13.17M
Enterprise Value$6.54M
Total Cash (Recent Filing)$22.68M
Total Debt (Recent Filing)$4.93M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Apr 17, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding16,999,626
10 Day Avg. Volume45,980,777
30 Day Avg. Volume32,599,391
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.37
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$6.17Price Target Upside681.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe P2b ReSPECT-GBM study is progressing with enrollment expected to complete soon, demonstrating targeted radiation exposure in initial imaging data.
FinancingPlus Therapeutics has secured financing to extend its operational runway with a $15.0M equity financing and a $50M stock purchase agreement.
Product DevelopmentPlus Therapeutics plans a full commercial launch of its CNSide diagnostic platform, which could play a critical role in monitoring therapy responses in the CNS.
Bears Say
Adverse EventsStock weakness following the data presentation comes from an overreaction to a reported dose-limiting toxicity (hemiplegia).
Capital RaisesFuture capital raises are now estimated to occur at significantly lower share prices than previously anticipated.
Stock Price TargetLowering the 12-month price target to $5.50 per share from $8.00 to account for the increased number of outstanding shares and warrants.
---
Ownership Overview
12.45% Insiders
1.53% Mutual Funds
9.51% Other Institutional Investors
75.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PSTV FAQ
What was Plus Therapeutics Inc’s price range in the past 12 months?
Plus Therapeutics Inc lowest stock price was $0.24 and its highest was $2.67 in the past 12 months.
What is Plus Therapeutics Inc’s market cap?
Plus Therapeutics Inc’s market cap is $13.17M.
When is Plus Therapeutics Inc’s upcoming earnings report date?
Plus Therapeutics Inc’s upcoming earnings report date is Apr 17, 2025 which is in 11 days.
How were Plus Therapeutics Inc’s earnings last quarter?
Plus Therapeutics Inc released its earnings results on Mar 27, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.117.
Is Plus Therapeutics Inc overvalued?
According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued.
Does Plus Therapeutics Inc pay dividends?
Plus Therapeutics Inc does not currently pay dividends.
What is Plus Therapeutics Inc’s EPS estimate?
Plus Therapeutics Inc’s EPS estimate is -0.25.
How many shares outstanding does Plus Therapeutics Inc have?
Plus Therapeutics Inc has 16,999,626 shares outstanding.
What happened to Plus Therapeutics Inc’s price movement after its last earnings report?
Plus Therapeutics Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -23.684%.
Which hedge fund is a major shareholder of Plus Therapeutics Inc?
Currently, no hedge funds are holding shares in PSTV
---
Company Description
Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers. Operating primarily in the biotechnology and pharmaceutical sectors, the company is dedicated to improving patient outcomes through the development of its proprietary Rhenium NanoLiposome platform, which is designed to deliver targeted radiation therapy directly to tumor sites.
---
PSTV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.Read More>---
PSTV Stock 12 Month Forecast
Average Price Target
$6.17
▲(681.01% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Adaptimmune Therapeutics
―
Cellectar Biosciences
―
Anavex Life Sciences
―
Cyclerion Therapeutics
―
Best Analysts Covering PSTV
1 Year
1 Year Success Rate
1/17 ratings generated profit
1 Year Average Return
-55.82%
reiterated a buy rating 9 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -55.82% per trade.
---